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1. IntroductIon
CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) 
IS A STANDARD, SAFE, AND EFFICACIOUS TREAT-
MENT FOR THE OBSTRUCTIVE SLEEP APNEA SYN-
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These practice parameters are an update of the previously published 
recommendations regarding the use of autotitrating positive airway 
pressure (APAP) devices for titrating pressures and treating adult 
patients with obstructive sleep apnea syndrome. Continuous positive 
airway pressure (CPAP) at an effective setting verified by attended 
polysomnography is a standard treatment for obstructive sleep apnea 
(OSA). APAP devices change the treatment pressure based on feed-
back from various patient measures such as airflow, pressure fluctu-
ations, or measures of airway resistance. These devices may aid in 
the pressure titration process, address possible changes in pressure 
requirements throughout a given night and from night to night, aid in 
treatment of OSA when attended CPAP titration has not or cannot be 
accomplished, or improve patient comfort. A task force of the Standards 
of Practice Committee of the American Academy of Sleep Medicine has 
reviewed the literature published since the 2002 practice parameter on 
the use of APAP. Current recommendations follow: (1) APAP devices 
are not recommended to diagnose OSA; (2) patients with congestive 
heart failure, patients with significant lung disease such as chronic ob-
structive pulmonary disease; patients expected to have nocturnal arte-
rial oxyhemoglobin desaturation due to conditions other than OSA (e.g., 
obesity hypoventilation syndrome); patients who do not snore (either 
naturally or as a result of palate surgery); and patients who have central 
sleep apnea syndromes are not currently candidates for APAP titration 
or treatment; (3) APAP devices are not currently recommended for split-
night titration; (4) certain APAP devices may be used during attended 
titration with polysomnography to identify a single pressure for use with 
standard CPAP for treatment of moderate to severe OSA; (5) certain 
APAP devices may be initiated and used in the self-adjusting mode for 
unattended treatment of patients with moderate to severe OSA without 
significant comorbidities (CHF, COPD, central sleep apnea syndromes, 
or hypoventilation syndromes); (6) certain APAP devices may be used 
in an unattended way to determine a fixed CPAP treatment pressure 
for patients with moderate to severe OSA without significant comorbidi-
ties (CHF, COPD, central sleep apnea syndromes, or hypoventilation 
syndromes); (7) patients being treated with fixed CPAP on the basis 
of APAP titration or being treated with APAP must have close clinical 
follow-up to determine treatment effectiveness and safety; and (8) a re-
evaluation and, if necessary, a standard attended CPAP titration should 
be performed if symptoms do not resolve or the APAP treatment other-
wise appears to lack efficacy.
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DROME (OSA), a common disorder with established detriment 
to quality of life and adverse consequences for cardiovascular 
health.1 Most of the published literature supporting CPAP ther-
apy derives from trials where the treatment pressure is estab-
lished by direct inspection of sleep and breathing parameters 
during attended polysomnographic recording while adjusting 
pressures to find a setting that essentially eliminates apneas and 
hypopneas in all sleep stages and body positions. In addition to 
allowing direct observation by trained technologists to guide 
pressure selection, titration under attended polysomnography 
allows for interventions to adjust mask fit, eliminate leak, and 
help the patient adapt to the initial CPAP experience.2
However, as noted in the previous review and practice pa-
rameters paper, there are some assumed or potential limitations 
associated with PSG-directed CPAP determinations. These 
include the cost and inconvenience of repeat PSG due to in-
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complete titrations, the potential bias of in-laboratory versus 
in-home environment, and the potential to prescribe pressures 
that are not suitable due to the inherent limited sampling intro-
duced when titration takes place over only one, or in the case 
of split-night studies, one-half night of recording. Pressure re-
quirements may change over time due to variability in weight, 
change in underlying medical conditions, or resolution of up-
per airway edema caused by repetitive apneas.3-5 One night of 
titration to eliminate respiratory events that occur during REM 
sleep or in supine positions may yield a therapeutic pressure 
estimate that is higher than that needed on average for effective 
therapy.6,7 Although some have suggested that higher pressures 
may hinder compliance in certain patients, in general there is 
little evidence to suggest that higher pressures systematically 
lead to worse compliance.8,9 Nonetheless, the desire to improve 
the efficacy and comfort of treatment and to simplify or improve 
pressure titration has inspired the development of autotitrating 
positive airway pressure (APAP) devices.9 The technology and 
use of APAP devices was reviewed in the evidence-based re-
view and practice parameters published in 2002.7 Since that 
time, though there has been little advance in technology, more 
experience and research using APAP devices suggested a need 
for an update of the practice parameters.
The purpose of this practice parameter paper is to present up-
dated recommendations for using APAP to determine the need 
for or to provide treatment for OSA. The American Academy 
of Sleep Medicine (AASM) has previously published prac-
tice parameters for CPAP and bilevel positive airway pressure 
(BPAP) therapy, and the recommendations here do not modify 
those guidelines.1 The AASM also has previously published 
practice parameters on the determination of CPAP pressure for 
the treatment of OSA.2 The recommendations here supplement 
those previous guidelines for using APAP to titrate CPAP or 
treat OSA.
2. methodS
The Standards of Practice Committee (SPC) of the AASM 
commissioned among its members four individuals with ex-
pertise in the use of APAP to conduct this review. These con-
tent experts were appointed in June, 2006 to review and grade 
evidence in the peer-reviewed scientific literature regarding the 
use of APAP. A search for articles on treatment of obstructive 
sleep apnea with autotitrating CPAP (APAP) was conducted 
using EMBASE, Ovid MEDLINE(R), Ovid MEDLINE(R) 
In-Process & Other Non-Indexed Citations, and the Cochrane 
Clinical Trial Registry, first on August 25, 2006, and updated on 
November 7, 2006. Key words for searches included autoCPAP, 
automatic CPAP, autotitrating CPAP, autoset, auto PAP, and au-
toadjusting CPAP. Each search was run separately and findings 
were merged. When the search was limited to articles published 
in English and regarding humans, a total of 167 articles were 
identified. Abstracts from these articles were reviewed to deter-
mine if they met inclusion criteria. Articles were included for 
evaluation if they had more than 9 subjects and if they compared 
APAP use with standard PSG directed CPAP therapy, a standard 
alternate therapy (oral appliance, surgery), or another APAP de-
vice. The articles had to address at least one of eight “PICO” 
questions (acronym standing for Patient, Population or Prob-
lem, provided a specific Intervention or exposure, after which a 
defined Comparison is performed on specified Outcomes) that 
were decided upon ahead of the review process.10 While the 
PICO questions do not map one-to-one with the practice param-
eters, they were designed to generate information that would 
be useful in updating the existing practice parameters. Articles 
meeting these criteria in addition to those identified by pearl-
ing (i.e., checking the reference sections of search results for 
articles otherwise missed) provided 22 articles for review and 
grading (see accompanying evidence table).
The grading of evidence was according to the suggestions of 
Sackett (Table 1). All evidence grading was performed by inde-
pendent review of the article by two members of the task force. 
Areas of disagreement were addressed by the task force until 
resolved. The strength of recommendations was determined by 
the entire AASM SPC as standards, guidelines, or options, as 
defined in Table 2. Overall, there were 8 Level I studies, 10 
Level II studies, 1 Level III study, and 1 Level IV study. One 
study had bearing on the review but was not graded, as it did not 
directly address any of the PICO questions (See Table 3).
Table 1—AASM Classification of Evidence
Evidence Levels Study Design
I Randomized, well-designed trials with low alpha 
and beta error*
II Randomized trials with high alpha and beta error*
III Nonrandomized concurrently controlled studies
IV Nonrandomized historically controlled studies
V Case series
Adapted from Sackett 10
*Alpha (type I error) refers to the probability that the null hypoth-
esis is rejected when in fact it is true (generally acceptable at 5% or 
less, or P <0.05). Beta (type II error) refers to the probability that 
the null hypothesis is mistakenly accepted when in fact it is false 
(generally trials accept a beta error of 0.20). The estimation of type 
II error is generally the result of a power analysis. The power analy-
sis takes into account the variability and the effect size to determine 
if sample size is adequate to find a difference in means when it is 
present (power generally acceptable at 80%-90%).
Table 2—AASM Levels of Recommendations
Term	 Definition
Standard This is a generally accepted patient care strategy 
that reflects a high degree of clinical certainty. The 
term standard generally implies the use of Level 
I evidence, which directly addresses the clinical 
issue, or overwhelming Level II evidence.
Guideline This is a patient care strategy that reflects a moder-
ate degree of clinical certainty. The term guideline 
implies the use of Level II evidence or a consensus 
of Level III evidence.
Option This is a patient care strategy that reflects uncer-
tain clinical use. The term option implies incon-
clusive or conflicting evidence or conflicting ex-
pert opinion.
Adapted from Eddy12
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The Board of Directors of the AASM approved these recom-
mendations. All members of the AASM Standards of Practice 
Committee and Board of Directors completed detailed conflict-
of-interest statements and were found to have no conflicts of 
interest with regard to this subject.
These practice parameters define principles of practice that 
should meet the needs of most patients in most situations. These 
guidelines should not, however, be considered inclusive of all 
proper methods of care or exclusive of other methods of care 
reasonably directed to obtaining the same results. The ultimate 
judgment regarding propriety of any specific care must be 
made by the physician in light of the individual circumstances 
presented by the patient, available diagnostic tools, accessible 
treatment options, and resources.
The AASM expects these guidelines to have an impact on 
professional behavior, patient outcomes, and, possibly, health 
care costs. These practice parameters reflect the state of knowl-
edge at the time of publication and will be reviewed, updated, 
and revised as new information becomes available.
3. recommendatIonS
3.1. aPaP is not recommended to diagnose oSa. (Standard)
Treatment for OSA must be based on a prior diagnosis of 
OSA by an established method.13 APAP devices are not intend-
ed for diagnostic purposes. This recommendation, although re-
worded, is unchanged from the previous parameter paper.6 We 
found no new evidence addressing the use of autotitrating de-
vices for the diagnosis of OSA.
3.2. Patients with congestive heart failure, significant lung 
disease such as chronic obstructive pulmonary disease, 
patients expected to have nocturnal arterial oxyhemoglobin 
desaturation due to conditions other than oSa (e.g., obesity 
hypoventilation syndrome), patients who do not snore (either 
naturally or as a result of palate surgery), and patients who have 
central sleep apnea syndromes are not currently candidates for 
aPaP titration or treatment. (Standard)
This recommendation is unchanged from the previous pa-
rameter paper.6 Most studies evaluating APAP, regardless of the 
technology used, exclude such patients because the sensors and 
algorithms identifying respiratory events may not be sensitive 
or specific under these circumstances.
3.3. aPaP devices are not currently recommended for split-night 
titration. (Standard)
This recommendation is unchanged from the previous pa-
rameter paper.6 None of the reviewed studies examined APAP 
under conditions of an initial diagnostic period followed by a 
titration period in the same overnight study.
3.4. certain aPaP devices may be used during attended titration 
with polysomnography to identify a single pressure for use 
with standard cPaP for treatment of moderate to severe oSa. 
(Guideline)
This recommendation is unchanged from the previous pa-
rameter paper, except that the severity of OSA is now speci-
fied.6 One potential use of APAP is to identify a single pressure 
Table 3—Summary of Evidence Grading for Pertinent Questions
PICO	Questions*	 Number	of	Articles	(22†)	 Oxford	Ratings**
How accurate is APAP in diagnosing OSA? 0 -
Is APAP effective in determining an optimal fixed CPAP when
  used in a monitored/in-laboratory setting? 4 I-1
   II-1
   III-1
   NS-1
Do APAP devices used in the sleep laboratory for titration perform similarly?  3 I-2
   II-1
Is APAP used outside the sleep laboratory effective in determining an optimal
  CPAP pressure for chronic fixed CPAP? 8 I-3
   III-3
   IV-1
   NS-1
Is APAP efficacious in chronic treatment of OSA? 11 I-5
   II-6
Is APAP efficacious in chronic treatment of UARS in an unmonitored home setting? 0 -
What are the outcomes of APAP applied to OSA suspects (but where the diagnosis
  is not yet certain, i.e., intention to treat analysis)  1 II-1
Can APAP be used to adjust CPAP pressures or in lieu of CPAP in patients not
  tolerating or benefiting from CPAP? 0 -
* PICO is an acronym made up of the components of a question framed about a given Patient, Population or Problem provided a specific 
Intervention or exposure after which a defined Comparison is performed on specified Outcomes.
**	Adapted	from	Eddy12
† Some references applied to more than one PICO question
NS = not specified
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for use with a standard CPAP device for subsequent treatment 
of OSA. The prior recommendation had been based on Level I 
and II evidence. Based upon that review, APAP devices using 
methods that monitor snoring, apnea or hypopnea by airflow, 
flow contour, and/or impedance by the forced oscillation tech-
nique may effectively determine a pressure to reduce sleep dis-
ordered breathing events to the same extent as standard CPAP. 
The updated review did not reveal new evidence directly com-
paring APAP titrations against technologist-directed PAP titra-
tions over a single night. However, four studies (1 Level I, 1 
Level II, 1 Level III, 1 not graded) evaluated different aspects of 
APAP effectiveness using polysomnography. One Level II ran-
domized crossover study compared clinical outcomes (change 
in Epworth Sleepiness Scale [ESS], adherence, and subjective 
preference) between patients randomly assigned fixed CPAP 
based upon a single night APAP titration or to chronic APAP 
therapy.14 There was no difference in improvement of ESS or 
measures of adherence, but APAP was more often the preferred 
treatment. Additionally, one Level I crossover design study 
compared PSG-directed CPAP titration in patients with mod-
erate to severe OSA with three different APAP devices during 
PSG over 4 consecutive nights.15 The devices using flow limita-
tion in addition to vibration to determine pressure changes per-
formed similarly to CPAP; the device using only vibration did 
not perform as well. There was no significant difference in con-
trol of the apnea hypopnea index (AHI) between CPAP and two 
of the APAP units tested (both algorithms based on flow limita-
tion plus vibration), but there was one APAP unit that achieved 
significantly less control of AHI and arousals (vibration only).15 
The maximum, mean, and 95th percentile pressures also varied 
between one of the APAP devices and the other two. Lloberes et 
al compared nighttime PSG-directed CPAP titration with day-
time PSG- and APAP-directed pressure titration. They found 
that daytime APAP-directed titration yielded a higher treatment 
pressure recommendation than PSG-directed methods but that 
the clinical outcomes for ESS and PAP adherence were simi-
lar.16 All reviewed studies were performed in patients with mod-
erate to severe OSA; there are no data for use in patients with 
mild OSA.
Several studies evaluated the differences in therapeutic pres-
sure determinations between differing APAP devices (2 Level 
I,15,17 1 Level II18). One study compared the 50th and 95th per-
centile pressure levels during one night of PSG in patients with 
OSA and found differences between a flow-sensing device and 
a forced oscillating technique device.17 Another study found 
that the 95th percentile was higher with a flow-sensing device 
than with a forced oscillating technique device (9.9 vs. 7.0 cm 
H2O).
18 The same was true for the 50th percentile pressures, 
and additionally, downloaded pressure tracings were visually 
different. This study was limited in that it did not provide any 
measure of sleep or actual control of breathing events. Togeth-
er, these three studies do not actually provide an evaluation 
of these measures for choosing a fixed CPAP level, but they 
provide evidence that use of percentile measures to determine 
effective pressure levels may have inherent limitations and be 
device specific. Evidence for APAP titration is specific to each 
device, including the particular version of software and device 
version. Additionally, as pointed out in the prior review, the op-
timized treatment pressure is not necessarily the pressure below 
which 95% of all titration pressures fall (the 95th percentile).7 
This is because a single night of titration may not find an ad-
equate sampling of body position and sleep stage for pressure 
to be selected purely on a percentile basis. Just as in technician-
directed PAP titrations, a careful review of the whole PSG is 
recommended to determine the optimal pressure.
3.5. Certain APAP devices may be initiated and used in the 
self-adjusting mode for unattended treatment of patients with 
moderate to severe OSA without significant comorbidities 
(CHF, COPD, central sleep apnea syndromes, or hypoventila-
tion syndromes). (Option)
This is a change from the prior practice parameter paper. 
The prior practice parameter (3.6) stated that use of unattended 
home APAP treatment “in CPAP-naïve patients is not currently 
established.”6 Our present review found 5 Level I19-23 and 6 
Level II14,24-28 studies pertinent to this treatment strategy. The 
reviewed evidence did not address patients with milder OSA 
(all subjects with AHI>15, except in one study with AHI>1021). 
The studies, although of increasing methodologic soundness, 
have strengths and weaknesses in addressing this parameter.
In general, all study populations were predominantly male 
with moderate to severe OSA and without central sleep apnea, 
CHF, COPD, or other disorders associated with hypoventila-
tion. Five studies evaluated patient groups that were completely 
CPAP naïve (1 Level I and 4 Level II), and four (2 Level I, and 
2 Level II) evaluated patients exposed only to CPAP titration 
but otherwise unfamiliar with CPAP therapy. In two studies, the 
study subjects were not CPAP naïve prior to APAP use, and the 
meta-analysis19 was heterogeneous in this respect. One study 
selected only patients requiring fixed CPAP >10 cm H2O,
29 and 
one study recruited patients with high variability in pressure 
requirements during CPAP titration.14 Another study compared 
APAP to treatment with titrated BPAP in patients with “difficult 
to treat” OSA, defined as (1) CPAP ≥12 cm H2O, (2) intolerance 
of CPAP treatment during one attended full-night CPAP titra-
tion, or (3) baseline central respiratory disturbances comprise 
≥10% of the AHI, which increased further under CPAP.20 Four 
protocols started APAP at home after in-laboratory PAP titra-
tions but did not use the information gained in setting the APAP 
device settings.14,20,29,30 One study initiated therapy at home after 
clinic instruction in APAP use in half of the patients and initi-
ated APAP use in the hospital in the remainder.25 One was a 
meta-analysis that did not state the conditions under which pa-
tients were started on APAP.19 There was no significant differ-
ence in outcome of the four studies (1 Level I19 3 Level II24,25,28) 
that assessed the effect of APAP vs. CPAP on improvement of 
AHI after 2 to 24 months of therapy. Of six studies evaluat-
ing improvement in ESS, 5 found no difference14,19,24,25,28 and 
1 found slightly more improvement30 in patients using APAP 
vs. fixed PAP. In four crossover studies, the majority of pa-
tients preferred treatment with APAP vs. fixed PAP. Overall, 
most studies document similar compliance between CPAP and 
APAP. Only one study showed superior compliance in patients 
using APAP vs. CPAP.29 Mean pressures were consistently low-
er with APAP vs. CPAP, but in one study, the 95th percentile 
pressure of APAP after 6 weeks exceeded the fixed CPAP pres-
sure determined by 1-night home APAP titration.28 There were 
also similar outcomes for improvement in measures of quality 
of life. Taken together, these studies form an increasing body 
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of evidence indicating that in populations resembling those 
tested and using specific devices, there is substantial clinical 
equivalency between home-initiated chronic APAP therapy and 
attended in-lab titrated PAP guided therapy for treatment of pa-
tients with moderate to severe OSA.
3.6. certain aPaP devices may be used in an unattended way 
to determine a fixed cPaP treatment pressure for patients with 
moderate to severe oSa without significant comorbidities (chf, 
coPd, central sleep apnea syndromes, or hypoventilation 
syndromes). (option)
This is a new practice parameter. The findings of the prior re-
view7 included one Level II31 and 4 Level IV32-35 studies that re-
lated to unattended APAP titrations to determine a fixed CPAP 
treatment level. One Level IV34 study using a device no longer 
clinically marketed was not successful in finding an effective 
pressure (Peff), but three Level IV
32,33,35 studies and one Level 
II31 study found 1-2 days of unattended APAP titration effective 
in arriving at an Peff comparable to PSG-directed CPAP titra-
tion (PSG-CPAP). Berkani et al (Level IV) and Fletcher et al 
(Level IV) applied APAP in an unmonitored setting to CPAP 
naïve patients found that the derived Peff brought the AHI ≤10 
in 80% and 77.7% of patients. Series et al (Level IV) found 
Peff from 1 or 2 weeks of unattended APAP titration similar to 
Peff from PSG-CPAP titration. Finally, Lloberes et al (Level II) 
found that a partially attended (in hospital, with the possibility 
of a nurse correcting mask fit if noted) APAP titration yielded 
equivalent Peff to attended PSG-CPAP derived Peff. In this latter 
study, the authors emphasized the importance of visual scoring 
of the pressure recordings to determine Peff.
The updated search found additional supportive evidence (3 
Level I,19,22,36 3 Level II,30,37,38 1 Level IV39). One Level I study 
randomized patients to three different titration methods: PSG-
CPAP, unattended APAP titration for 1-3 nights, or a formula-
driven empirical pressure that was subsequently adjusted based 
on clinical variables.36 Patients in all three groups received 
standardized instruction and 20 minutes of exposure to CPAP 
during an afternoon session for mask fit and acclimatization. 
Successful unattended titration of APAP required a minimum 
of 1 night with at least 6 hours of total recording, and at least 
5 hours with a mean mask leak <0.4 L/sec. Successful titra-
tion was accomplished in 1-3 attempts in 96% of 119 patients. 
Peff was determined visually by inspection of raw data with a 
low leak and was taken as the 90th percentile pressure from 
those segments. This study did not directly compare treatment 
pressures between methods within the same patient, but instead 
compared clinical outcomes when treatment was based on dif-
ferent titration methods. There was no statistical difference in 
the AHI, arousal index, oxygenation during sleep, ESS, PAP 
adherence, or Functional Outcomes of Sleep Questionnaire 
(FOSQ) scores between groups titrated with APAP vs. PSG-
CPAP, but the physical and mental axis of the SF36 and the Eu-
roQol Index (a non-disease specific instrument for measuring 
health-related quality of life) improved slightly less in APAP 
titrated patients compared with PSG-CPAP titrated patients. 
This study provided the strongest support for this parameter. 
Senn et al studied 29 patients in a randomized crossover trial 
comparing 1 month of therapy on a fixed CPAP setting derived 
as the 90th percentile of pressure from 2 weeks of APAP with 1 
month of therapy using two different APAP devices.22 Subjec-
tive and objective measures of sleepiness improved similarly 
in all three treatment arms, and a cardiorespiratory study at the 
end of the treatment period found all three treatment modali-
ties provided good and similar control of apneas, hypopneas, 
and oxygenation parameters. However, this study did not com-
pare outcomes in patients treatment with APAP directed CPAP 
settings to those of patients treated with CPAP settings deter-
mined by PSG. The meta-analysis by Ayas contains reference to 
APAP-directed CPAP settings, but was not designed to directly 
assess this use of APAP.
The studies reviewed for this review show equivalence in 
some, but not all parameters in patient outcomes when titration 
was based on unmonitored APAP as compared with PSG-CPAP 
titration. The available evidence supporting this practice is im-
proving, but several issues remain to be settled. The required 
duration of APAP monitoring required, the best particular de-
rived pressure (i.e., 90th percentile, 95th percentile, etc.), and 
which APAP algorithms and software provide accuracy all re-
main to be determined in most cases. It is important to stress 
that the cited evidence was specific to each device (devices are 
listed in the evidence table), including the particular version of 
software and device version, and that pressure determination 
should be made by experienced sleep specialists after examina-
tion of the raw pressure titration data for each patient. For these 
reasons, the committee did not find consensus that the available 
evidence supported a guideline recommendation. Polysomnog-
raphy directed CPAP titration is still the standard method for 
determination of effective CPAP pressure.
3.7. Patients being treated with fixed cPaP on the basis of aPaP 
titration or being treated with aPaP must have close clinical 
follow up to determine treatment effectiveness and safety. this 
is especially important during the first few weeks of PaP use. 
(Standard)
This is in agreement with the prior practice parameter (la-
beled [7] in the prior document).6 Methods to assess the patient 
may include questionnaires measuring sleepiness and continued 
snoring, follow-up polysomnograms or cardiorespiratory stud-
ies, assessment of physical conditions such as an increase in 
weight, and capturing information stored on the APAP or CPAP 
devices, including time on device, time at pressure, pressure 
and leak profiles, and residual apneas/hypopneas (if available). 
As noted in the recent CPAP and BPAP therapy practice param-
eters article, there are data to suggest that follow-up soon after 
initiating PAP is associated with better outcomes of long term 
adherence.1 While this has not been explicitly evaluated in pa-
tients using APAP, the same admonition seems reasonable.
3.8. a reevaluation and, if necessary, a standard attended cPaP 
titration should be performed if symptoms do not resolve 
or if the aPaP treatment otherwise appears to lack efficacy. 
(Standard)
This is unchanged from the prior practice parameter (labeled 
[8] in the prior document).6 Unresolved clinical symptoms 
should prompt a clinical reevaluation with attention to issues 
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such as mask fit, mask leak, use of device, weight change, and 
other clinical observations. A download of information from the 
APAP devices may reveal useful information, such as excessive 
mask leak, or an excess of apneas or hypopneas, which may 
guide decisions for further evaluation or treatment. If necessary, 
a standard in-laboratory CPAP titration with polysomnography 
should be performed to document or determine the efficacy of 
the CPAP or APAP treatment.1,40
4.0 areaS for future reSearch
4.1 In order for aPaP to better apply to usual clinical 
circumstances, studies are needed that clarify which patients 
can and cannot be served by aPaP devices, with particular 
attention to subjects with mild oSa or comorbidities.
4.2 Since different technologies are used, at times with 
variable results, further research may be able to determine 
which technologies are most appropriate for specific patient 
groups. development of industry standards in design, technical 
performance against standard flow profiles, and reporting would 
be beneficial and would assist practitioners in recognition and 
understanding of the underlying technologies.
4.3 the optimal way to derive the Peff from attended and 
unattended aPaP titrations is not standardized. more research is 
needed to determine which parameters are most important, how 
much mask leak is tolerable, and what durations of monitoring 
provide the best titrations. Similarly, since most available 
research does not find pressure a major determinant of patient 
acceptance and adherence, defining which patient specific 
factors will be most predictive of significant gains with aPaP is 
of importance in deciding patient assignment to treatments.
4.4 economic evaluations involving the use of aPaP in titration 
or chronic therapy compared with PSG-cPaP, oral appliances, 
or surgery are few or lacking. the place of aPaP therapy in 
the sleep specialist’s armamentarium is dependent on a better 
understanding of cost-benefit analysis of using these advanced 
technologies.
4.5 most aPaP devices have accompanying software that allows 
downloading of series data to a computer. the parameters 
reported vary from device to device, and the best use of the 
parameters is not yet the subject of research. Study is needed 
to validate the accuracy of certain parameters (e.g., aPaP-
determined residual ahI). Study may also illuminate which 
parameters are most helpful in guiding therapy, so that those 
factors can be standardized.
referenceS
1. Kushida CA, Littner MR, Hirshkowitz M, et al. Practice param-
eters for the use of continuous and bilevel positive airway pres-
sure devices to treat adult patients with sleep-related breathing 
disorders. Sleep 2006;29:375-80.
2. Littner MR, Kushida C, Wise M, et al. Practice parameters for 
clinical use of the multiple sleep latency test and the maintenance 
of wakefulness test. Sleep 2005;28:113-21.
3. Ryan CF, Lowe AA, Li D, Fleetham JA. Magnetic resonance im-
aging of the upper airway in obstructive sleep apnea before and af-
ter chronic nasal continuous positive airway pressure therapy.[see 
comment]. Am Rev Resp Dis 1991;144:939-44.
4. Collop NA, Block AJ, Hellard D. The effect of nightly nasal 
CPAP treatment on underlying obstructive sleep apnea and pha-
ryngeal size. Chest 1991;99:855-60.
5. Mortimore IL, Kochhar P, Douglas NJ. Effect of chronic continu-
ous positive airway pressure (CPAP) therapy on upper airway 
size in patients with sleep apnoea/hypopnoea syndrome. Thorax 
1996;51:190-2.
6. Littner M, Hirshkowitz M, Davila D, et al. Practice parameters 
for the use of auto-titrating continuous positive airway pressure 
devices for titrating pressures and treating adult patients with ob-
structive sleep apnea syndrome. An American Academy of Sleep 
Medicine report. Sleep 2002;25:143-7.
7. Berry RB, Parish JM, Hartse KM. The use of auto-titrating con-
tinuous positive airway pressure for treatment of adult obstructive 
sleep apnea. An American Academy of Sleep Medicine review. 
Sleep 2002;25:148-73.
8. Gay P, Weaver T, Loube D, Iber C. Evaluation of positive airway 
pressure treatment for sleep related breathing disorders in adults: 
A review by the positive airway pressure task force of the Stan-
dards of Practice Committee of the American Academy of Sleep 
Medicine. Sleep 2006;29:381-401.
9. Krieger J. Therapeutic use of auto-CPAP. Sleep Med Rev 
1999;3:159-74.
10. Sackett D. Rules of evidence and clinical recommendations for 
the management of patients. Can J Cardiol 1993;9:487-9.
11. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength 
of recommendations and quality of evidence in clinical guide-
lines: report from an American College of Chest Physicians Task 
Force.[see comment]. Chest 2006;129:174-81.
12. Eddy D, ed. A manual for assessing health practices and design-
ing practice policies: the explicit approach. Philadelphia, PA: 
American College of Physicians; 1992.
13. Littner M, Hirshkowitz M, Kramer M, et al. Practice parameters 
for using polysomnography to evaluate insomnia: an update. 
Sleep 2003;26:754-60.
14. Marrone O, Resta O, Salvaggio A, Giliberti T, Stefano A, Insa-
laco G. Preference for fixed or automatic CPAP in patients with 
obstructive sleep apnea syndrome. Sleep Med 2004;5:247-51.
15. Stammnitz A, Jerrentrup A, Penzel T, Peter JH, Vogelmeier C, 
Becker HF. Automatic CPAP titration with different self-setting 
devices in patients with obstructive sleep apnoea. Eur Respir J 
2004;24:273-8.
16. Lloberes P, Rodriguez B, Roca A, et al. Comparison of conven-
tional nighttime with automatic or manual daytime CPAP titra-
tion in unselected sleep apnea patients: study of the usefulness of 
daytime titration studies. Respir Med 2004;98:619-25.
17. Pevernagie DA, Proot PM, Hertegonne KB, Neyens MC, Hoorn-
aert KP, Pauwels RA. Efficacy of flow- vs impedance-guided au-
toadjustable continuous positive airway pressure: a randomized 
cross-over trial. Chest 2004;126:25-30.
18. Kessler R, Weitzenblum E, Chaouat A, Iamandi C, Alliotte T. 
Evaluation of unattended automated titration to determine thera-
peutic continuous positive airway pressure in patients with ob-
structive sleep apnea. Chest 2003;123:704-10.
19. Ayas NT, Patel SR, Malhotra A, et al. Auto-titrating versus 
standard continuous positive airway pressure for the treatment 
of obstructive sleep apnea: results of a meta-analysis. Sleep 
2004;27:249-53.
20. Randerath WJ, Galetke W, Ruhle KH. Auto-adjusting CPAP 
based on impedance versus bilevel pressure in difficult-to-treat 
sleep apnea syndrome: a prospective randomized crossover study. 
Med Sci Monit 2003;9:CR353-8.
SLEEP, Vol. 31, No. 1, 2008 147
21. Randerath WJ, Schraeder O, Galetke W, Feldmeyer F, Ruhle KH. 
Autoadjusting CPAP therapy based on impedance efficacy, com-
pliance and acceptance. Am J Respir Crit Care Med 2001;163(3 
Pt 1):652-7.
22. Senn O, Brack T, Matthews F, Russi EW, Bloch KE. Randomized 
short-term trial of two autoCPAP devices versus fixed continuous 
positive airway pressure for the treatment of sleep apnea. Am J 
Respir Crit Care Med 2003;168:1506-11.
23. Nolan GM, Ryan S, O’Connor TM, McNicholas WT. Compari-
son of three auto-adjusting positive pressure devices in patients 
with sleep apnoea. Eur Respir J 2006;28:159-64.
24. Planes C, D’Ortho MP, Foucher A, et al. Efficacy and cost of 
home-initiated auto-nCPAP versus conventional nCPAP. Sleep 
2003;26:156-60.
25. Nussbaumer Y, Bloch KE, Genser T, Thurnheer R. Equivalence 
of autoadjusted and constant continuous positive airway pressure 
in home treatment of sleep apnea. Chest 2006;129:638-43.
26. Hertegonne KB, Proot PM, Pauwels RA, Pevernagie DA. Com-
fort and pressure profiles of two auto-adjustable positive airway 
pressure devices: a technical report. Respir Med 2003;97:903-8.
27. Massie CA, Hart RW. Clinical outcomes related to interface 
type in patients with obstructive sleep apnea/hypopnea syn-
drome who are using continuous positive airway pressure. Chest 
2003;123:1112-8.
28. West SD, Jones DR, Stradling JR. Comparison of three ways to 
determine and deliver pressure during nasal CPAP therapy for ob-
structive sleep apnoea. Thorax 2006;61:226-31.
29. Massie CA, McArdle N, Hart RW, et al. Comparison between 
automatic and fixed positive airway pressure therapy in the home. 
Am J Respir Crit Care Med 2003;167:20-3.
30. Noseda A, Kempenaers C, Kerkhofs M, Braun S, Linkowski P, 
Jann E. Constant vs auto-continuous positive airway pressure in 
patients with sleep apnea hypopnea syndrome and a high vari-
ability in pressure requirement. Chest 2004;126:31-7.
31. Lloberes P, Ballester E, Montserrat JM, et al. Comparison of 
manual and automatic CPAP titration in patients with sleep ap-
nea/hypopnea syndrome. Am J Respir Crit Care Med 1996;154(6 
Pt 1):1755-8.
32. Berkani M, Lofaso F, Chouaid C, et al. CPAP titration by an 
auto-CPAP device based on snoring detection: a clinical tri-
al and economic considerations.[see comment]. Eur Respir J 
1998;12:759-63.
33. Fletcher EC, Stich J, Yang KL. Unattended home diagnosis and 
treatment of obstructive sleep apnea without polysomnography. 
Arch Fam Med 2000;9:168-74.
34. Juhasz J, Schillen J, Urbigkeit A, Ploch T, Penzel T, Peter JH. 
Unattended continuous positive airway pressure titration. Clini-
cal relevance and cardiorespiratory hazards of the method. Am J 
Respir Crit Care Med 1996;154(2 Pt 1):359-65.
35. Series F. Accuracy of an unattended home CPAP titration in the 
treatment of obstructive sleep apnea. Am J Respir Crit Care Med 
2000;162:94-7.
36. Masa JF, Jimenez A, Duran J, et al. Alternative methods of ti-
trating continuous positive airway pressure: a large multicenter 
study. Am J Respir Crit Care Med 2004;170:1218-24.
37. Resta O, Carratu P, Depalo A, et al. Effects of fixed compared to 
automatic CPAP on sleep in obstructive sleep apnoea syndrome. 
Monaldi Arch Chest Dis 2004;61:153-6.
38. Hukins C. Comparative study of autotitrating and fixed-pressure 
CPAP in the home: A randomized, single-blind crossover trial. 
Sleep 1512;27:1512-7.
39. Palombini L, Guilleminault C. Stroke and treatment with nasal 
CPAP. Eur J Neurol 2006;13:198-200.
40. Kushida CA, Littner MR, Morgenthaler T, et al. Practice param-
eters for the indications for polysomnography and related proce-
dures: an update for 2005. Sleep 2005;28:499-521.
